Sulfonylurea drugs, commonlyused in type 2 diabetes mellitus treatment, bind to the octamer KATPchannels composed of four pore-forming Kir6.2 and four SUR1 subunitsand increase the probability of insulin release. The gene discussed is ABCC8; the disease is diabetes mellitus.